Elephas Biosciences, Neuberg Partner on Immuno-therapy Testing
The Story: Elephas Biosciences has partnered with Neuberg Diagnostics to bring its elive live-tissue platform to India, with a clinical test planned by the end of 2026.
The Take: The partnership adds functional immunotherapy testing to India’s precision oncology landscape and could help oncologists better match patients with effective treatments.
Biodeal Pharmaceuticals Raises ₹385 Crore
The Story: Biodeal Pharmaceuticals has raised ₹385 crore from RMB Capitalworks to expand its specialty pharma portfolio, manufacturing capacity, and global presence.
The Take: The funding will support faster expansion across regulated markets and strengthen Biodeal’s position in specialty pharma, with an IPO also on the horizon.
Zydus Launches Once-Daily Nebulized COPD Therapy
The Story: Zydus Lifesciences has launched Revahale (revefenacin), India’s first once-daily nebulized LAMA for COPD maintenance treatment.
The Take: The launch offers a simpler option for elderly and severe COPD patients who struggle with inhaler devices, potentially improving treatment adherence and daily symptom control.
Dr. Reddy’s to End Novartis India Partnership
The Story: Dr. Reddy’s will end its distribution and promotion agreement with Novartis India by September 30, 2026, following a change in Novartis India’s ownership.
The Take: Novartis will regain control of the affected brands, while Dr. Reddy’s will lose the associated distribution revenue from Q4 202
PayU, Marg ERP Partner on Pharma Payments
The Story: PayU and Marg ERP have partnered to launch Marg Pay, enabling digital collections and automated reconciliation for pharma distributors and retailers.
The Take: The partnership could streamline pharma payments, speed up collections, and expand digital adoption across India’s B2B pharma distribution network.
Gland Pharma Signs CDMO Deal for 55 Injectables
The Story: Gland Pharma has signed a CDMO deal to manufacture and supply 55 sterile injectable products for global markets, with revenues expected from 2029.
The Take: The deal could add $90–100M in annual revenue and strengthen Gland’s position in the global sterile injectable CDMO market.
